Trulieve Cannabis (NYSE: TRLV) is trading around $11.50–$11.55 as of the June 11 close (latest available data this morning, June 12).
It closed up modestly +0.43% ($0.05) on solid volume (~1.1M shares), but it's been volatile since its historic NYSE debut on June 10. The stock opened around $11.78–$11.89, hit intraday highs near $12.30–$12.00, and has seen swings in the $10.26–$13.28 range recently.
Quick Performance Breakdown (post-uplisting vibe):
- 52-week range: $3.25 low to $13.28 high — it's been on a tear longer-term (YTD strong, 1-year returns north of 200% in some metrics), riding rescheduling tailwinds.
- Market cap: ~$2.2B.
The listing itself sparked initial pops (strong volume, up over 4% intraday on debut day), fueled by the first major U.S. plant-touching cannabis operator hitting a big-boy exchange — a direct ripple from Schedule III moves opening institutional doors. They also dropped a $50M share buyback signal of confidence.
This is classic cannabis sector grind: hype on legitimacy milestones meets the raw reality of ongoing federal gray areas, state regs, and market chop. For The Stoner Review crowd in NJ, it's proof the industry's maturing — big operators like Trulieve positioning for banking relief, lower taxes on medical ops, and broader investor access while the streets and small players keep it real. Ties perfectly into that rescheduling battle.
For content/merch angle: Frame this as "The suits finally let one in the door — now watch the real ones thrive." Could spark a "NYSE Stoner" or "Schedule III Drip" tee concept with gritty NYSE floor meets neon joint energy. Or a blog post breaking down what it means for NJ operators, backyard growers, and everyday patients. Readers eat up honest takes on the grind from OTC shadows to Wall Street lights.
Want a deeper chart dive, peer comparison, or fresh mockup prompts spun from these visuals? Let's turn this market smoke into loyal traffic and merch that moves.
